Embecta Corp. Common Stock (EMBC)

Price$3.38

Value ScoreA

Growth ScoreD

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-81.43%

Price vs S&P 500 (4W)-7.13%

VGM Score46.74

Market Capitalization$200.53M

P/E Ratio (Annual)2.10x

Indicated Dividend Yield (Annual)13.49%

All Metrics

P/CF (Annual)1.05x

Book Value / Share (Quarterly)$-14.33

Indicated Dividend (Annual)$0.04

Revenue Growth (3Y)-1.47%

Cash Flow / Share (Quarterly)$3.45

Payout Ratio (TTM)25.16%

Price vs S&P 500 (YTD)-79.71%

Gross Margin (TTM)61.94%

Net Profit Margin (TTM)10.73%

EPS (TTM)$1.90

10-Day Avg Trading Volume1.69M

EPS Excl Extra (TTM)$1.90

Revenue Growth (5Y)-0.10%

EPS (Annual)$1.62

Dividend / Share (Annual)$0.60

ROI (Annual)69.87%

Gross Margin (Annual)63.86%

Net Profit Margin (5Y Avg)15.50%

Cash / Share (Quarterly)$3.12

P/E Basic Excl Extra (TTM)1.79x

Revenue Growth QoQ (YoY)-14.36%

EPS Growth (5Y)-26.19%

P/E Normalized (Annual)2.10x

ROA (Last FY)8.75%

Revenue Growth TTM (YoY)-3.43%

EBITD / Share (TTM)$5.27

Operating Margin (TTM)25.78%

Cash Flow / Share (Annual)$3.12

P/B Ratio0.36x

Net Income / Employee (Annual)$51,600

EV / Revenue (TTM)1.32x

Net Interest Coverage (TTM)2.27x

ROA (TTM)10.31%

EV / EBITDA (TTM)4.41x

EPS Incl Extra (Annual)$1.62

Current Ratio (Annual)2.41x

Quick Ratio (Quarterly)1.38x

3-Month Avg Trading Volume1.59M

52-Week Price Return-66.13%

EV / Free Cash Flow (Annual)7.53x

P/E Incl Extra (TTM)1.79x

Revenue / Employee (TTM)$563,500

Tangible BV / Share (Quarterly)$-14.76

P/S Ratio (Annual)0.19x

Asset Turnover (Annual)0.99x

52-Week High$15.55

Operating Margin (5Y Avg)25.33%

EPS Excl Extra (Annual)$1.62

CapEx CAGR (5Y)-26.03%

26-Week Price Return-73.50%

Quick Ratio (Annual)1.44x

13-Week Price Return-64.19%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.46x

Enterprise Value$1.37B

Revenue / Share Growth (5Y)-0.45%

Asset Turnover (TTM)0.96x

Revenue / Employee (Annual)$584,000

Inventory Turnover (Annual)2.23x

Pretax Margin (Annual)12.62%

Cash / Share (Annual)$3.85

3-Month Return Std Dev123.54%

Gross Margin (5Y Avg)66.70%

Net Income / Employee (TTM)$60,500

EBITDA CAGR (5Y)-11.64%

EBITDA Interim CAGR (5Y)-19.84%

ROE (Last FY)69.87%

Net Interest Coverage (Annual)2.71x

EPS Basic Excl Extra (Annual)$1.62

P/FCF (TTM)0.98x

Receivables Turnover (TTM)6.27x

EV / Free Cash Flow (TTM)6.71x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$1.90

Receivables Turnover (Annual)6.36x

ROI (TTM)8.55%

P/S Ratio (TTM)0.19x

Pretax Margin (5Y Avg)18.24%

Revenue / Share (Annual)$18.34

Tangible BV / Share (Annual)$-14.76

Forward P/E2.02x

Free OCF CAGR (5Y)-16.78%

Price vs S&P 500 (52W)-90.50%

P/E Ratio (TTM)1.79x

EPS Growth TTM (YoY)108.44%

Year-to-Date Return-71.55%

5-Day Price Return2.74%

EPS Normalized (Annual)$1.62

ROA (5Y Avg)18.78%

Net Profit Margin (Annual)8.83%

Month-to-Date Return0.00%

Cash Flow / Share (TTM)$1.79

EBITD / Share (Annual)$4.80

EPS Growth (3Y)-25.33%

Operating Margin (Annual)22.41%

P/CF (TTM)0.94x

P/E Excl Extra (TTM)1.79x

EPS Basic Excl Extra (TTM)$1.90

Payout Ratio (Annual)36.69%

Dividend / Share (TTM)$0.60

Inventory Turnover (TTM)2.19x

Pretax Margin (TTM)16.27%

Book Value / Share (Annual)$-14.33

Price vs S&P 500 (13W)-72.45%

Net Margin Growth (5Y)-25.86%

Dividend Yield (TTM)17.60%

Beta0.83x

P/FCF (Annual)1.10x

Revenue / Share (TTM)$17.58

ROE (TTM)6.12%

52-Week Low$2.77

vGradeA

gGradeD

mGradeF

vgmGradeC

Show chart for

Earnings Surprise History

Q2 260.27est. 0.43

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

2.56

2.33

Industry Peers — Surgical & Medical Instruments(138)

Symbol	Value Score	Growth Score	Momentum Score	Price
EMBCEmbecta Corp. Common Stock	A	D	F	$3.38
SYKStryker Corporation	C	C	C	$305.66
MMM3M Company	C	F	C	$153.76
BSXBoston Scientific Corp.	C	B	D	$48.55
MDLNMedline Inc. Class A common stock	C	D	D	$33.61
BDXBecton, Dickinson and Co.	B	C	C	$151.16
RMDResMed Inc.	C	B	C	$196.04
DXCMDexCom, Inc.	C	B	C	$72.86
WSTWest Pharmaceutical Services, Inc.	D	C	B	$314.50
SOLVSolventum Corporation	C	D	B	$81.01
PENPenumbra, Inc.	F	C	B	$320.53

About

Embecta Corp manufactures diabetes care products including insulin pen needles, syringes, and safety devices sold through wholesalers and distributors, with the majority of revenue from the United States. The company also offers a proprietary digital application for diabetes management and provides contract manufacturing services.